← All trials
NCT05507216
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2022
- Primary completion
- May 31, 2024
- Completion date
- Jun 30, 2024
- First posted
- Aug 18, 2022
- Last posted
- Nov 17, 2022
- Enrollment
- 612
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Abivax S.A.Lead sponsor
- Katholieke Universiteit LeuvenOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.